Product Information
ABILIFY MAINTENA ER 400 MG VL is a brand product labeled by Otsuka America Pharmaceutical Inc., priced at $2856.9237 per EA under NDC 59148024512. Its NADAC has been published 63 times since Jun 11, 2025.
FDA first approved this application on Feb 28, 2013.
The High Outlier badge above means this manufacturer's average price in the aripiprazole market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Manufacturer
Otsuka America Pharmaceutical Inc.NDC
59148024512
Classification
Brand
Dosage Form
KIT
Effective Date
8/19/2026
Approval Type
New Drug (NDA)
FDA Application
NDA202971FDA Approved
2/28/2013
On Market Since
2/28/2025
Price Statistics
The NADAC for ABILIFY MAINTENA ER 400 MG VL has been published 63 times since Jun 11, 2025, and over the history we have for it it has risen 2.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $2856.9237 per EA |
|---|---|
| All-time high | $2860.9798 (Jul 15, 2026) |
| All-time low | $2771.0251 (Oct 22, 2025) |
| 52-week high | $2860.9798 |
| 52-week low | $2771.0251 |
| Median price | $2855.8774 |
| Average price | $2817.1335 |
| Largest weekly change | +3.0% (Jan 14, 2026) |
| Weeks tracked | 63 |
| Tracking since | Jun 11, 2025 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 25% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of ABILIFY MAINTENA ER 400 MG VL?
The current National Average Drug Acquisition Cost (NADAC) for ABILIFY MAINTENA ER 400 MG VL, manufactured by Otsuka America Pharmaceutical Inc., is $2856.9237 per EA (NDC 59148024512), effective Aug 19, 2026.
How has the price of ABILIFY MAINTENA ER 400 MG VL changed over time?
Over the history we have for it, the NADAC for ABILIFY MAINTENA ER 400 MG VL has risen 2.9%. It has been tracked across 63 weekly CMS publications since Jun 11, 2025.
What are the highest and lowest recorded NADAC prices for ABILIFY MAINTENA ER 400 MG VL?
Since Jun 11, 2025, the NADAC for ABILIFY MAINTENA ER 400 MG VL has ranged from a low of $2771.0251 (Oct 22, 2025) to a high of $2860.9798 (Jul 15, 2026), with a median of $2855.8774 per EA.
Are there cheaper alternatives to ABILIFY MAINTENA ER 400 MG VL?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, ABILIFY MAINTENA ER 300 MG VL, is $2138.9070 per EA — about 25% below ABILIFY MAINTENA ER 400 MG VL.
Who manufactures ABILIFY MAINTENA ER 400 MG VL?
ABILIFY MAINTENA ER 400 MG VL (NDC 59148024512) is labeled by Otsuka America Pharmaceutical Inc., and CMS classifies it as a brand product.